查詢結果分析
相關文獻
- 新型超長效胰島素製劑--Insulin Degludec
- Orbital Rhinocerebral Mucormycosis Associated with Diabetic Ketoacidosis: Report of Survival of a 10-Year-Old Boy
- Role of an Outpatient Clinic in Screening Chronic Complications of Diabetes: A Model for Diabetes Managed Care
- Evaluation of the Pain-Relieving Effect of Carbamazepine (Tegretol[feb9]) during Panretinal Photocoagulation
- 糖尿病病人血清中銅、鋅與紅血球超氧化物歧變酶的測定
- 糖尿病與高脂血症
- Pulmonary Mucormycosis--Two Survived Cases Report
- ACARBOSE使用於口服降糖藥物失效之第2型糖尿病患者--臨床評估
- 大黃及其有效成分(Emodin)對糖尿病腎病變治療效果之研究
- 治療第二型糖尿病藥物Repaglinide
第1筆 /總和 1 筆
/ 1 筆
頁籤選單縮合
題名 | 新型超長效胰島素製劑--Insulin Degludec=New Ultra Long-acting Insulin--Insulin Degludec |
---|---|
作者姓名(中文) | 施美份; 吳士慧; 蔡璧玲; | 書刊名 | 藥學雜誌 |
卷期 | 33:4=133 2017.12[民106.12] |
頁次 | 頁76-81 |
分類號 | 418.271 |
關鍵詞 | 糖尿病; 胰島素製劑; Insulin degludec; |
語文 | 中文(Chinese) |
中文摘要 | 糖尿病人口數目逐年攀升,主要病人為第二型糖尿病人,因血糖控制不良導致的 併發症仍是這個疾病的致死主要因素。第二型糖尿病人雖然不需要依賴注射胰島素存 活,但是多數人仍在某個階段需開始注射胰島素以期達到較佳的血糖控制目的。速效 型胰島素提供便利性,而長效型胰島素製劑 (Insulin glargine 及 Insulin detemir) 提供 基礎胰島素濃度,主要是協助維持兩餐之間及夜間的血糖穩定,但卻不宜與速效型 製劑合併。剛上市的 Insulin degludec 具有超長效作用,且可以與速效型製劑或是與 Glucagon-like peptide-1 (GLP-1) 製劑混合注射提供相對的方便性,相較起其他兩個長 效性型胰島素製劑其個體之間差異小且安全性亦無差異。 |
英文摘要 | The majority of diabetes is type II, mortality raised from chronic complications due to poor blood glucose control. Insulin treatment in type II diabetes is not for survival but may be required for optimal blood glucose control eventually. Insulin glargine and Insulin detemir provide basal insulin level, but they are not recommended to combine with short acting insulin; while new ultra long-acting insulin, Insulin degludec, provides long duration, safety, and convenience. Insulin degludec can be easily combined with rapid acting insulin or Glucagon-like peptide-1 (GLP-1) analogs. In addition Insulin degludec induces less individual difference and nocturnal hypoglycemia than that seen in long acting insulin. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。